Cargando…

Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease

Light chain deposition disease (LCDD) is a rare systemic disorder caused by the deposition of light chain immunoglobulins, which often results in renal impairment associated with either nephrotic syndrome or asymptomatic proteinuria. B-cell neoplasms, such as multiple myeloma and lymphoproliferative...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimura, Satoshi, Ohkawara, Hiroshi, Ogawa, Kazuei, Tanaka, Mizuko, Sano, Takahiro, Harada-Shirado, Kayo, Takahashi, Hiroshi, Ueda, Koki, Shichishima-Nakamura, Akiko, Matsumoto, Hayato, Ikeda, Kazuhiko, Kazama, Junichiro James, Hashimoto, Yuko, Ikezoe, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355407/
https://www.ncbi.nlm.nih.gov/pubmed/30101913
http://dx.doi.org/10.2169/internalmedicine.1018-18
Descripción
Sumario:Light chain deposition disease (LCDD) is a rare systemic disorder caused by the deposition of light chain immunoglobulins, which often results in renal impairment associated with either nephrotic syndrome or asymptomatic proteinuria. B-cell neoplasms, such as multiple myeloma and lymphoproliferative disorders, are well-known underlying diseases in LCDD. Some chemotherapy regimens have been reported, but both evidence-based treatment and management for LCDD have yet to be established. We herein report three cases of LCDD treated with lenalidomide-based therapy, resulting in hematologic responses accompanied by a significant reduction in proteinuria and improvement in the renal function. We recommend lenalidomide-based therapy for renal impairment caused by LCDD.